ADO Annual Report 2014, page-31

A few of my thoughts {in italics} about the Chairman's and CEO's reports, that struck me particularly.

Page 4 of our CEO’s report:

The development of products by our scientific team enables a more intimate level of interaction with potential customers by ‘demystifying’ the technology and translating it directly into an adaptable product offering. This means we can proactively demonstrate the technology and we can work closely with existing and new partners to identify the Mix&Go formulation and protocols that will enable them to harness the significant efficiencies, savings and advantages associated with Mix&Go.

{We have often speculated and been frustrated by the apparent slow speed of uptake of the technology; perhaps we expect too much of many scientists and organisations, to perceive what to us seems bleeding obvious. I can see better why the range of 50 products from the 3 we had last year, is so important.}

Operations:
In FY 14 we appointed five senior scientists. Since the last report we have expanded the business development capability and most recently appointed a USA based VP Scientific Affairs, Mr Josh Soldo. The range of activities completed successfully, and outlined in this report, has resulted in greater organisational control. Anteo is well positioned to accelerate its recent growth and expand the applications of Mix&Go within healthcare, from diagnostics to separations and conceivably to in vivo applications such as drug delivery, and into industrial uses.

{The highlighted phrases are self-explanatory; the issue of organisational control harks back to our Chairman’s comment about “Anteo has matured as a company”, and “has achieved commercial traction and a reputation for entrepreneurial and dynamic problem-solving.”}

Brand Development and Market Outreach:
By providing the market with ready-to-use research we will not only generate sales revenue, but more importantly we will actively engage research and development teams that will gain a hands-on understanding of the unique capabilities of Mix&Go. This approach also allows us to build many of our ‘trade secrets’ into the products thereby capturing greater value from our expertise as well as our proprietary technology. Combined with other efforts, this step will be instrumental in broadening the market awareness, knowledge and excitement about our technology. . . . Anteo can create high value products that should increase the success rates for third parties testing Mix&Go for the first time, without a significant drain on our internal resources. Our initial experience confirms this. The barrier to initial feasibility testing has been lowered.

{I like that part about retaining the” trade secrets” in house, enhancing prospects’ dependence on Anteo, while at the same time these products, being ‘test ready’, don’t require nearly the level of support that used to be the case.}

The PCT announcement relating to ‘Conjugating Molecules to Particles’ is significant . . .

{Read again the rest of this paragraph about this PCT, will you? Multiple tests in one go, anyone? This is huge!}